Risk stratification according to cytogenetics in 408 patients from the study cohort according to Grimwade23,24
| Refined Medical Research Council criteria23,24 . | No. of cases (%) . |
|---|---|
| Intermediate risk group | 366 (89.7) |
| Normal karyotype | 281 (68.9) |
| Other non-complex | 85 (20.8) |
| Adverse risk group | 42 (10.3) |
| Complex alterations | 21 (5.1) |
| −7/add(7q) | 11 (2.7) |
| del(5q)/−5/add(5q) | 6 (1.5) |
| Others* | 4 (1.0) |
| Total* | 408 (100) |
| Refined Medical Research Council criteria23,24 . | No. of cases (%) . |
|---|---|
| Intermediate risk group | 366 (89.7) |
| Normal karyotype | 281 (68.9) |
| Other non-complex | 85 (20.8) |
| Adverse risk group | 42 (10.3) |
| Complex alterations | 21 (5.1) |
| −7/add(7q) | 11 (2.7) |
| del(5q)/−5/add(5q) | 6 (1.5) |
| Others* | 4 (1.0) |
| Total* | 408 (100) |
Cases with “others” were represented by deletions, other aberrations, and cases with independent clones as classified according to Medical Research Council criteria.